Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Vall d'Hebron Hospital Universitari · Vall d'Hebron Institute of Oncology · +24 more institutions
Abstract
V600E-mutated metastatic colorectal cancer, including as first-line therapy. Data on progression-free survival (the second primary end point) and an updated interim analysis of overall survival are now available.
V600E-mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care. The two primary end points were objective response (reported previously) and progression-free survival according to blinded independent central review in the EC+mFOLFOX6 group and the standard-care group. The key secondary end point was overall survival.
Citation impact
- FWCI
- 78.10
- Percentile
- 100%
- References
- 20
Authors
20- EÉElena ÉlezCorresponding
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- TYTakayuki Yoshino
National Cancer Center Hospital East
- LSLin Shen
Peking University, Peking University Cancer Hospital
- SLSara Lonardi
Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico
- EVEric Van Cutsem
Universitair Ziekenhuis Leuven, KU Leuven
Topics & keywords
- Cetuximab
- Colorectal cancer
- Oncology
- Cancer
- Medicine
- Internal medicine
- Cancer research
- Good health and well-being